Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 44856-44857 [E9-20932]
Download as PDF
<![CDATA[
44856
Federal Register / Vol. 74, No. 167 / Monday, August 31, 2009 / Notices
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Katharine Kripke,
Assistant Director, Vaccine Research
Program, Division of AIDS, NIAID, NIH,
6700B Rockledge Dr., Bethesda, MD
20892–7628, or call non-toll-free
number 301–402–0846, or E-mail your
request, including your address to
NIAIDsurvey@NIH.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: August 25, 2009.
J.J. McGowan,
Executive Officer, NIAID, National Institutes
of Health.
[FR Doc. E9–20882 Filed 8–28–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
cprice-sewell on DSK2BSOYB1PROD with NOTICES
Advisory Board on Radiation and
Worker Health: Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Board on Radiation and
Worker Health, Department of Health
and Human Services, has been renewed
for a 2-year period through August 3,
2011.
For information, contact Mr.
Theodore Katz, Executive Secretary,
Advisory Board on Radiation and
Worker Health, Department of Health
and Human Services, 1600 Clifton Road,
M/S E20, Atlanta, Georgia, 30341,
telephone 404/498–2533, or fax 404/
498–2570.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
VerDate Nov<24>2008
14:57 Aug 28, 2009
Jkt 217001
meetings and other committee
management activities, for both the CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: August 19, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–20958 Filed 8–28–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln Ave.,
West Allis, WI 53227. 414–328–7840/800–
877–7016. (Formerly: Bayshore Clinical
Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove
Park, Rochester, NY 14624. 585–429–2264.
Advanced Toxicology Network, 3560 Air
Center Cove, Suite 101, Memphis, TN
38118. 901–794–5770/888–290–1150.
Aegis Analytical Laboratories, 345 Hill Ave.,
Nashville, TN 37210. 615–255–2400.
(Formerly: Aegis Sciences Corporation,
Aegis Analytical Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little Rock,
AR 72205–7299. 501–202–2783. (Formerly:
Forensic Toxicology Laboratory Baptist
Medical Center.)
Clendo Reference Laboratory, Avenue Santa
Cruz #58, Bayamon, Puerto Rico 00959.
787–620–9095.
Clinical Reference Lab, 8433 Quivira Road,
Lenexa, KS 66215–2802. 800–445–6917.
Doctors Laboratory, Inc., 2906 Julia Drive,
Valdosta, GA 31602. 229–671–2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns
Road, Warminster, PA 18974. 215–674–
9310.
DynaLIFE Dx,* 10150–102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2. 780–
451–3702/800–661–9876. (Formerly:
Dynacare Kasper Medical Laboratories.)
ElSohly Laboratories, Inc., 5 Industrial Park
Drive, Oxford, MS 38655. 662–236–2609.
Gamma-Dynacare Medical Laboratories,* A
Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall
Street, London, ONT, Canada N6A 1P4.
519–679–1630.
Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053. 504–361–
E:\FR\FM\31AUN1.SGM
31AUN1
cprice-sewell on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 167 / Monday, August 31, 2009 / Notices
8989/800–433–3823. (Formerly: Laboratory
Specialists, Inc.)
Kroll Laboratory Specialists, Inc., 450
Southlake Blvd., Richmond, VA 23236.
804–378–9130. (Formerly: Scientific
Testing Laboratories, Inc.; Kroll Scientific
Testing Laboratories, Inc.)
Laboratory Corporation of America Holdings,
7207 N. Gessner Road, Houston, TX 77040.
713–856–8288/800–800–2387.
Laboratory Corporation of America Holdings,
69 First Ave., Raritan, NJ 08869. 908–526–
2400/800–437–4986. (Formerly: Roche
Biomedical Laboratories, Inc.)
Laboratory Corporation of America Holdings,
1904 Alexander Drive, Research Triangle
Park, NC 27709. 919–572–6900/800–833–
3984. (Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of Roche
Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A Member
of the Roche Group.)
Laboratory Corporation of America Holdings,
1120 Main Street, Southaven, MS 38671.
866–827–8042/800–233–6339. (Formerly:
LabCorp Occupational Testing Services,
Inc.; MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics, 10101
Renner Blvd., Lenexa, KS 66219. 913–888–
3927/800–873–8845. (Formerly: Quest
Diagnostics Incorporated; LabOne, Inc.;
Center for Laboratory Services, a Division
of LabOne, Inc.)
Maxxam Analytics,* 6740 Campobello Road,
Mississauga, ON, Canada L5N 2L8. 905–
817–5700. (Formerly: Maxxam Analytics
Inc., NOVAMANN (Ontario), Inc.)
MedTox Laboratories, Inc., 402 W. County
Road D, St. Paul, MN 55112. 651–636–
7466/800–832–3244.
MetroLab-Legacy Laboratory Services, 1225
NE 2nd Ave., Portland, OR 97232. 503–
413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical Center,
Forensic Toxicology Laboratory, 1 Veterans
Drive, Minneapolis, MN 55417. 612–725–
2088.
National Toxicology Laboratories, Inc., 1100
California Ave., Bakersfield, CA 93304.
661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc., 1213
Genoa-Red Bluff, Pasadena, TX 77504.
888–747–3774. (Formerly: University of
Texas Medical Branch, Clinical Chemistry
Division; UTMB Pathology-Toxicology
Laboratory.)
Pacific Toxicology Laboratories, 9348 DeSoto
Ave., Chatsworth, CA 91311. 800–328–
6942. (Formerly: Centinela Hospital
Airport Toxicology Laboratory.)
Pathology Associates Medical Laboratories,
110 West Cliff Dr., Spokane, WA 99204.
509–755–8991/800–541–7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road,
San Diego, CA 92121. 858–643–5555.
Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340. 770–
452–1590/800–729–6432. (Formerly:
SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 400 Egypt
Road, Norristown, PA 19403. 610–631–
4600/877–642–2216. (Formerly:
VerDate Nov<24>2008
14:57 Aug 28, 2009
Jkt 217001
SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 7600 Tyrone
Ave., Van Nuys, CA 91405. 866–370–6699/
818–989–2521. (Formerly: SmithKline
Beecham Clinical Laboratories.)
S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109. 505–727–
6300/800–999–5227.
South Bend Medical Foundation, Inc., 530 N.
Lafayette Blvd., South Bend, IN 46601.
574–234–4176 x276.
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix, AZ
85040. 602–438–8507/800–279–0027.
St. Anthony Hospital Toxicology Laboratory,
1000 N. Lee St., Oklahoma City, OK 73101.
405–272–7052.
STERLING Reference Laboratories, 2617 East
L Street, Tacoma, Washington 98421. 800–
442–0438.
Toxicology & Drug Monitoring Laboratory,
University of Missouri Hospital & Clinics,
301 Business Loop 70 West, Suite 208,
Columbia, MO 65203. 573–882–1273.
Toxicology Testing Service, Inc., 5426 NW.
79th Ave., Miami, FL 33166. 305–593–
2260.
U.S. Army Forensic Toxicology Drug Testing
Laboratory, 2490 Wilson St., Fort George G.
Meade, MD 20755–5235. 301–677–7085.
* The Standards Council of Canada (SCC)
voted to end its Laboratory Accreditation
Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified
through that program were accredited to
conduct forensic urine drug testing as
required by U.S. Department of
Transportation (DOT) regulations. As of that
date, the certification of those accredited
Canadian laboratories will continue under
DOT authority. The responsibility for
conducting quarterly performance testing
plus periodic on-site inspections of those
LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS’
NLCP contractor continuing to have an active
role in the performance testing and
laboratory inspection processes. Other
Canadian laboratories wishing to be
considered for the NLCP may apply directly
to the NLCP contractor just as U.S.
laboratories do.
Upon finding a Canadian laboratory to be
qualified, HHS will recommend that DOT
certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards
of the Mandatory Guidelines published in the
Federal Register on April 13, 2004 (69 FR
19644). After receiving DOT certification, the
laboratory will be included in the monthly
list of HHS-certified laboratories and
participate in the NLCP certification
maintenance program.
Elaine Parry,
Director, Office of Program Services,
SAMHSA.
[FR Doc. E9–20932 Filed 8–28–09; 8:45 am]
BILLING CODE 4162–20–P
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
44857
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
Coordinating Center for Health
Promotion (BSC, CCHP or the BSC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Time and Date: 1 p.m.–5 p.m., September
15, 2009.
The call may end before 5 p.m. if business
is completed. Someone will remain on the
line until that time to notify callers that the
call is ended and business complete.
Place: Teleconference originating from
CDC, 1825 Century Boulevard, NE., Room
4066, Atlanta, Georgia 30345.
Call-in number: (800) 779–9076.
Participant pass code: 39780.
If you have a problem in accessing the call,
call (404) 498–6700.
Status: This meeting is open to the public
via the conference line above which will
accommodate approximately 100 callers.
Purpose: This BSC is charged with
providing advice and guidance to the
Secretary of Health and Human Services, the
Director of CDC, and the Director of CCHP
concerning strategies and goals for the
programs and research within the National
Center on Birth Defects and Developmental
Disabilities and the National Center for
Chronic Disease Prevention and Health
Promotion.
Matters To Be Discussed: The agenda will
include a continuation of the discussion and
finalization of recommendations to CDC
leadership as prescribed in the Coordinating
Center for Health Promotion Charter. Those
recommendations relate to strategic planning
for the National Center on Birth Defects and
Developmental Disabilities as well as the
results of the BSC’s review of the National
Center for Chronic Disease Prevention and
Health Promotion as an organizational unit at
CDC.
Providing Oral or Written Comments: It is
the policy of the BSC, CCHP to provide a
brief period for oral public comments. In
general, each individual or group requesting
to make an oral presentation will be limited
to a total time of five minutes, if time
permits.
Contact Person for Additional Information:
Karen Steinberg, PhD, Senior Science Officer,
Coordinating Center for Health Promotion,
CDC, 4770 Buford Highway, NE., Mailstop E–
70, Atlanta, Georgia 30341; telephone (404)
498–6700; fax (404) 498–6880; or via e-mail
at Karen.Steinberg@cdc.hhs.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
CDC and the Agency for Toxic Substances
and Disease Registry.
E:\FR\FM\31AUN1.SGM
31AUN1
]]>Agencies
[Federal Register Volume 74, Number 167 (Monday, August 31, 2009)]
[Notices]
[Pages 44856-44857]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20932]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Public Law
100-71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified, an applicant laboratory must undergo three rounds of
performance testing plus an on-site inspection. To maintain that
certification, a laboratory must participate in a quarterly performance
testing program plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227. 414-
328-7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY
14624. 585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101,
Memphis, TN 38118. 901-794-5770/888-290-1150.
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210.
615-255-2400. (Formerly: Aegis Sciences Corporation, Aegis
Analytical Laboratories, Inc.)
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7,
Little Rock, AR 72205-7299. 501-202-2783. (Formerly: Forensic
Toxicology Laboratory Baptist Medical Center.)
Clendo Reference Laboratory, Avenue Santa Cruz 58, Bayamon,
Puerto Rico 00959. 787-620-9095.
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802.
800-445-6917.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602. 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA
18974. 215-674-9310.
DynaLIFE Dx,* 10150-102 St., Suite 200, Edmonton, Alberta, Canada
T5J 5E2. 780-451-3702/800-661-9876. (Formerly: Dynacare Kasper
Medical Laboratories.)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS
38655. 662-236-2609.
Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT,
Canada N6A 1P4. 519-679-1630.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA
70053. 504-361-
[[Page 44857]]
8989/800-433-3823. (Formerly: Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond,
VA 23236. 804-378-9130. (Formerly: Scientific Testing Laboratories,
Inc.; Kroll Scientific Testing Laboratories, Inc.)
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040. 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan,
NJ 08869. 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709. 919-572-6900/800-833-3984.
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A
Member of the Roche Group.)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671. 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219. 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a
Division of LabOne, Inc.)
Maxxam Analytics,* 6740 Campobello Road, Mississauga, ON, Canada L5N
2L8. 905-817-5700. (Formerly: Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112.
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232. 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417. 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304. 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504. 888-747-3774. (Formerly: University of Texas
Medical Branch, Clinical Chemistry Division; UTMB Pathology-
Toxicology Laboratory.)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311. 800-328-6942. (Formerly: Centinela Hospital Airport
Toxicology Laboratory.)
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204. 509-755-8991/800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121. 858-
643-5555.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA
30340. 770-452-1590/800-729-6432. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA
19403. 610-631-4600/877-642-2216. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA
91405. 866-370-6699/818-989-2521. (Formerly: SmithKline Beecham
Clinical Laboratories.)
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM
87109. 505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601. 574-234-4176 x276.
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040. 602-438-8507/800-279-0027.
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101. 405-272-7052.
STERLING Reference Laboratories, 2617 East L Street, Tacoma,
Washington 98421. 800-442-0438.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia,
MO 65203. 573-882-1273.
Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL
33166. 305-593-2260.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD 20755-5235. 301-677-7085.
* The Standards Council of Canada (SCC) voted to end its
Laboratory Accreditation Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified through that program
were accredited to conduct forensic urine drug testing as required
by U.S. Department of Transportation (DOT) regulations. As of that
date, the certification of those accredited Canadian laboratories
will continue under DOT authority. The responsibility for conducting
quarterly performance testing plus periodic on-site inspections of
those LAPSA-accredited laboratories was transferred to the U.S. HHS,
with the HHS' NLCP contractor continuing to have an active role in
the performance testing and laboratory inspection processes. Other
Canadian laboratories wishing to be considered for the NLCP may
apply directly to the NLCP contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards of the Mandatory
Guidelines published in the Federal Register on April 13, 2004 (69
FR 19644). After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program.
Elaine Parry,
Director, Office of Program Services, SAMHSA.
[FR Doc. E9-20932 Filed 8-28-09; 8:45 am]
BILLING CODE 4162-20-P
